Dr. Reddy’s Laboratories launches Olanzapine Tablets

India Infoline News Service | Mumbai |

The ZYPREXA Tablets brand and generic had combined U.S. sales of approximately $3.28 billion for the most recent twelve months ending January 2012 according to IMS Health.

Dr. Reddy’s Laboratories announced today that it has launched Olanzapine Tablets (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg), a bioequivalent generic version of ZYPREXA Tablets in the US market on April 23, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Olanzapine Tablets.

Dr. Reddy’s Olanzapine Tablets in 20 mg had been awarded a 180-day period of marketing exclusivity in the U.S. on October 26, 2011 which was commercialized through a commercial, manufacture and supply agreement with Teva Pharmaceutical Industries Ltd.

The ZYPREXA Tablets brand and generic had combined U.S. sales of approximately $3.28 billion for the most recent twelve months ending January 2012 according to IMS Health.

Dr. Reddy’s Olanzapine Tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg strengths are available in 30 and 500 count bottles.

BSE 2,416.00 [11.30] ([0.47]%)
NSE 2,419.95 [7.75] ([0.32]%)

***Note: This is a NSE Chart

 

Advertisements

  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.
welcome to iifl